InsiderTrades.com logo
The “Next Bitcoin”? 10 CENT Crypto Set to Explode
From True Market Insiders   |   Ad
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…
Click For My #1 FREE Crypto for 2024
Uma Sinha net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Uma Sinha Biography and Net Worth

Insider of Eidos Therapeutics
Uma Sinha, Ph.D., is the chief scientific officer of Eidos Therapeutics. She has extensive experience in discovery and preclinical development of agents targeting pathogenesis of hematologic, cardiovascular, and inflammatory diseases. Before joining Eidos, Dr. Sinha served as chief scientific officer of Global Blood Therapeutics. Previously, she was vice president and head of biology at Portola Pharmaceuticals and held senior research positions at Millennium Pharmaceuticals and COR Therapeutics. During her tenure at COR, Dr. Sinha and her team were responsible for the initiation and progression of factor Xa inhibitor programs that led to the development of betrixaban, which is currently awaiting FDA approval as the first anticoagulant for extended duration venous thromboembolism prophylaxis in acute medically ill patients. Dr. Sinha has led the development of five novel agents currently in advanced clinical trials or awaiting FDA approval.

She has authored or co-authored 70 scientific articles in peer-reviewed journals and is a named inventor in 25 issued U.S. patents. Dr. Sinha holds a Ph.D. in biochemistry from the University of Georgia and received her postdoctoral training in pathology and chemistry at the State University of New York, Stony Brook.

What is Uma Sinha's net worth?

The estimated net worth of Uma Sinha is at least $38.83 million as of December 2nd, 2020. Ms. Sinha owns 317,727 shares of Eidos Therapeutics stock worth more than $38,829,417 as of April 29th. This net worth evaluation does not reflect any other assets that Ms. Sinha may own. Additionally, Ms. Sinha receives a salary of $533,400.00 as Insider at Eidos Therapeutics. Learn More about Uma Sinha's net worth.

How old is Uma Sinha?

Ms. Sinha is currently 64 years old. There are 5 older executives and no younger executives at Eidos Therapeutics. Learn More on Uma Sinha's age.

What is Uma Sinha's salary?

As the Insider of Eidos Therapeutics, Inc., Ms. Sinha earns $533,400.00 per year. The highest earning executive at Eidos Therapeutics is Dr. Cameron Turtle DPHIL, Ph.D., Chief Bus. Officer, who commands a salary of $578,400.00 per year. Learn More on Uma Sinha's salary.

How do I contact Uma Sinha?

The corporate mailing address for Ms. Sinha and other Eidos Therapeutics executives is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. Eidos Therapeutics can also be reached via phone at 415-887-1471 and via email at [email protected]. Learn More on Uma Sinha's contact information.

Has Uma Sinha been buying or selling shares of Eidos Therapeutics?

Uma Sinha has not been actively trading shares of Eidos Therapeutics during the last ninety days. Most recently, Uma Sinha sold 5,000 shares of the business's stock in a transaction on Wednesday, December 2nd. The shares were sold at an average price of $90.04, for a transaction totalling $450,200.00. Following the completion of the sale, the insider now directly owns 317,727 shares of the company's stock, valued at $28,608,139.08. Learn More on Uma Sinha's trading history.

Who are Eidos Therapeutics' active insiders?

Eidos Therapeutics' insider roster includes Jonathan Fox (Insider), Uma Sinha (Insider), Cameron Turtle (Insider), and Franco Valle (SVP). Learn More on Eidos Therapeutics' active insiders.

Uma Sinha Insider Trading History at Eidos Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/2/2020Sell5,000$90.04$450,200.00317,727View SEC Filing Icon  
10/29/2020Sell5,000$72.42$362,100.00325,225View SEC Filing Icon  
9/30/2020Sell169$52.03$8,793.07331,456View SEC Filing Icon  
9/25/2019Sell2,500$38.41$96,025.00
7/25/2019Sell5,000$36.13$180,650.00View SEC Filing Icon  
5/23/2019Sell5,000$27.28$136,400.00View SEC Filing Icon  
See Full Table

Uma Sinha Buying and Selling Activity at Eidos Therapeutics

This chart shows Uma Sinha's buying and selling at Eidos Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eidos Therapeutics Company Overview

Eidos Therapeutics logo
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.
Read More

Today's Range

Now: $122.21
Low: $122.21
High: $122.21

50 Day Range

MA: $123.21
Low: $120.98
High: $128.51

2 Week Range

Now: $122.21
Low: $28.39
High: $132.54

Volume

N/A

Average Volume

128,113 shs

Market Capitalization

$4.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
The “Next Bitcoin”? 10 CENT Crypto Set to Explode
From True Market Insiders   |   Ad
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…
Click For My #1 FREE Crypto for 2024